Titlebook: Diagnosis and Management of Testicular Cancer; The European Point o Susanne Krege Book 2015 Springer International Publishing Switzerland 2

Narrative

Book 2015the field. It opens by providing an overview of the recommendations in the most recent consensus paper from the European Germ Cell Cancer Consensus Group, which is based on interdisciplinary cooperation among urologists, medical oncologists, radio-oncologists, pathologists, and basic scientists. The

CURB

Latest Recommendations of the European Germ Cell Cancer Group on Diagnosis and Treatment of Germ Cele et al. Eur Urol 53:497–513, 2008), the latest published in 2012 (Beyer et al. Ann Oncol 24:878–888, 2013). In this chapter, the recent recommendations of the European group are summarized. The following chapters will present some topics in detail, which are still discussed controversial, or for which the best management is not yet found.

Innocence

How Should Patients with Recurrent Disease Be Treated Actually?of HDCT as first-line salvage therapy in relapsed patients with highly favorable risk profiles. In order to avoid overtreatment, HDCT should only be administered at specialist centres with the necessary expertise.

PLIC

Prognostic Factors at Initial Presentation and in Recurrent Diseaseisease. This discussion has been presented in the previous chapters of this book. The other one will be presented here and focuses on the much more pressing question of survival probabilities in patients with metastatic disease.

Anemia

https://doi.org/10.1007/978-1-4842-9830-5 follow-up has to be tailored to each individual patient, and the schedule has to be acceptable for the patient, the physician, as well as the health-care system [2]. The interval of follow-up visits and the tests to be performed at each visit depend on the risk of relapse in general and on the likely site of relapse in particular [2, 3].

ALLEY

Robust

consolidate

NEX

NOT

https://doi.org/10.1007/978-1-4842-9830-5isease. This discussion has been presented in the previous chapters of this book. The other one will be presented here and focuses on the much more pressing question of survival probabilities in patients with metastatic disease.